Murae Organisor Limited, formerly known as Earum Pharmaceuticals Limited, is a publicly traded company in the pharmaceutical sector, incorporated in 2012 and restructured in 2019. The company specializes in the marketing, trading, and distribution of a diverse array of pharmaceutical formulation products, including antibiotics, anti-malarial, anti-inflammatory, neurological, and dermatology drugs, among others. It currently offers approximately 125 products, with 24 marketed under its own brand, outsourcing manufacturing to third parties. Additionally, Murae Organisor is involved in the trading of active pharmaceutical ingredients (APIs), such as Levofloxacin Hemihydrate IP and Amoxicillin Trihydrate IP.
In June 2019, the company successfully raised Rs 6.65 Crore through an Initial Public Offering (IPO), issuing 18,48,000 equity shares. This capital infusion supports its growth and operational activities within the pharmaceutical industry.
